Public University Corporation Yokohama City University

Nagasaki University

Yokohama City University

Nagoya City University

Chiome Beoscience Inc.

Yokohama City University and Chiome Bioscience Inc.

Chiome Bioscience Inc.

Yoshio Goshima

Naoya Yamashita

Shuichi Hashimoto

Koji Murakami

Hidetaka Seo

Naoki Takahashi

Fumio Nakamura

Yukie Sasakura

Keita Takahashi

Hiroshi Ueda

Takayoshi Suzuki

Naoki Miyata

Ryuta Hiraishi

Kohtaro Takei

Yume Suzuki

Yoshifumi Nishimura

Aritaka Nagadoi

Yuuka Hirao

The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.

Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same

Novel means useful for definitive diagnosis of a neurological disease accompanied by at least one of inflammation and demyelination, such as multiple sclerosis or neuromyelitis optica, is disclosed. The method for detecting a neurological disease (excluding cerebral infarction) accompanied by at least one of inflammation and demyelination provided by the present invention comprises measuring Crtac1B protein in a sample separated from a subject. The presence of the neurological disease is detected based on a low value of the Crtac1B protein level.

Method for detecting neurological disease accompanied by inflammation and/or demyelination

The present invention identifies a compound which binds to the PAH1 domain of mSin3B that specifically binds to neural restrictive silencer factor NRSF, and uses the compound as a prophylactic and/or a therapeutic for diseases associated with abnormal expression of neural restrictive silencer factor NRSF/REST or abnormal expression of genes targeted by NRSF/REST, such as Huntington's disease, medulloblastoma and neuropathic pain. The present invention provides a pharmaceutical composition comprising a substance capable of binding to the PAH1 domain of mSin3B, e.g., a compound represented by the following formula (1), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof: wherein n represents 0 or 1; R, R, R, Rand Reach independently represent a hydrogen atom, a hydrocarbon group or a functional group; Y represents a single bond, a carbonyl group, &#x2014;CONH&#x2014;, &#x2014;NHCO&#x2014; or a sulfonyl group; and Z represents a nitrogen-containing heterocyclic group which may have a substituent, an amino group which may have a hydrocarbon group or an aromatic hydrocarbon group, or a nitrogen and oxygen-containing heterocyclic group which may have a substituent.

Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF)

Growing community of inventors

Yokohama, Japan

Yoshio Goshima